

Clinical Oversight Review Board (CORB) Criteria for Prescribing for Coverage

Epcoritamab - bysp (Epkinly)

Notes:

- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **epcoritamab- bysp (Epkinly)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-Formulary **epcoritamab -bysp (Epkinly)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by oncologist/Hematologist
- Patient is at least 18 years of age
- Patient has a diagnosis of either relapsed or refractory diffuse large B-cell lymphoma (DLBCL) -AND- have failed and adequate trial of glofitamab and two systemic lines of chemotherapy
-OR-
- Relapsed/refractory follicular lymphoma (FL) – AND- have failed and adequate trial of mosunetuzumab and two lines of systemic chemotherapy

Criteria for *current Kaiser Permanente members already taking the medication who have not been reviewed previously:* Non-Formulary **epcoritamab -bysp (Epkinly)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by oncologist/Hematologist
- Patient is at least 18 years of age
- Patient has a diagnosis of either relapsed or refractory diffuse large B-cell lymphoma (DLBCL) -AND- have failed and adequate trial of glofitamab and two systemic lines of chemotherapy
-OR-
- Relapsed/refractory follicular lymphoma (FL) – AND- have failed and adequate trial of mosunetuzumab and two lines of systemic chemotherapy

Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:* Non-Formulary **epcoritamab – bysp (Epkinly)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by oncologist/Hematologist

kp.org

Revised: 09/12/24
Effective: 11/21/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Clinical Oversight Review Board (CORB) Criteria for Prescribing for Coverage

Epcoritamab - bysp (Epkinly)

- Patient is at least 18 years of age
- Patient has a diagnosis of either relapsed or refractory diffuse large B-cell lymphoma (DLBCL) -AND- have failed and adequate trial of glofitamab and two systemic lines of chemotherapy
-OR-
- Relapsed/refractory follicular lymphoma (FL) – AND- have failed and adequate trial of mosunetuzumab and two lines of systemic chemotherapy

kp.org

Revised: 09/12/24
Effective: 11/21/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest